TY - JOUR
T1 - Clinical Heterogeneity of the VEXAS Syndrome
T2 - A Case Series
AU - Koster, Matthew J.
AU - Kourelis, Taxiarchis
AU - Reichard, Kaaren K.
AU - Kermani, Tanaz A.
AU - Beck, David B.
AU - Cardona, Daniela Ospina
AU - Samec, Matthew J.
AU - Mangaonkar, Abhishek A.
AU - Begna, Kebede H.
AU - Hook, C. Christopher
AU - Oliveira, Jennifer L.
AU - Nasr, Samih H.
AU - Tiong, Benedict K.
AU - Patnaik, Mrinal M.
AU - Burke, Michelle M.
AU - Michet, Clement J.
AU - Warrington, Kenneth J.
N1 - Publisher Copyright:
© 2021 Mayo Foundation for Medical Education and Research
PY - 2021/10
Y1 - 2021/10
N2 - The objective of this study is to describe the clinical features and outcomes of patients with the newly defined vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Nine men with somatic mutations in the UBA1 gene were identified; the most frequent variant was p.Met41Thr (7 of 9, 78%). The median age at VEXAS diagnosis was 74 (67, 76.5) years, and patients had a median duration of symptoms for 4 years before diagnosis. Refractory constitutional symptoms (88%), ear and nose chondritis (55%), and inflammatory arthritis (55%) were common clinical features. Vasculitis was noted in 44%. All patients had significantly elevated inflammatory markers and macrocytic anemia. Thrombocytopenia was present in 66% at diagnosis of VEXAS. Eight patients had bone marrow biopsies performed. All bone marrows were hypercellular, and there was vacuolization of the erythroid (100%) or myeloid precursors (75%). Glucocorticoids attenuated symptoms at prednisone doses ≥20 mg per day, but no other immunosuppressive agent showed consistent long-term control of disease. One patient with coexisting plasma-cell myeloma received plasma-cell–directed therapy with improvement of the inflammatory response, which is a novel finding. In conclusion, VEXAS syndrome is a clinically heterogeneous, treatment-refractory inflammatory condition caused by somatic mutation of the UBA1 gene. Patients often present with overlapping rheumatologic manifestations and persistent hematologic abnormalities. As such, internists and subspecialists, including pathologists, should be aware of this condition to avert diagnostic delay, now that the etiology of this syndrome is known.
AB - The objective of this study is to describe the clinical features and outcomes of patients with the newly defined vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Nine men with somatic mutations in the UBA1 gene were identified; the most frequent variant was p.Met41Thr (7 of 9, 78%). The median age at VEXAS diagnosis was 74 (67, 76.5) years, and patients had a median duration of symptoms for 4 years before diagnosis. Refractory constitutional symptoms (88%), ear and nose chondritis (55%), and inflammatory arthritis (55%) were common clinical features. Vasculitis was noted in 44%. All patients had significantly elevated inflammatory markers and macrocytic anemia. Thrombocytopenia was present in 66% at diagnosis of VEXAS. Eight patients had bone marrow biopsies performed. All bone marrows were hypercellular, and there was vacuolization of the erythroid (100%) or myeloid precursors (75%). Glucocorticoids attenuated symptoms at prednisone doses ≥20 mg per day, but no other immunosuppressive agent showed consistent long-term control of disease. One patient with coexisting plasma-cell myeloma received plasma-cell–directed therapy with improvement of the inflammatory response, which is a novel finding. In conclusion, VEXAS syndrome is a clinically heterogeneous, treatment-refractory inflammatory condition caused by somatic mutation of the UBA1 gene. Patients often present with overlapping rheumatologic manifestations and persistent hematologic abnormalities. As such, internists and subspecialists, including pathologists, should be aware of this condition to avert diagnostic delay, now that the etiology of this syndrome is known.
UR - http://www.scopus.com/inward/record.url?scp=85114216375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114216375&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2021.06.006
DO - 10.1016/j.mayocp.2021.06.006
M3 - Article
C2 - 34489099
AN - SCOPUS:85114216375
SN - 0025-6196
VL - 96
SP - 2653
EP - 2659
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 10
ER -